Astrocytes as Pharmacological Targets in the Treatment of Schizophrenia: Focus on Kynurenic Acid

Handbook of Behavioral Neuroscience

Volumn 23, Issue , 2016, Pages 423-443

  Pocivavsek, Ana ^a   Notarangelo, Francesca M ^a   Wu, Hui Qiu ^a   Bruno, John P ^b   Schwarcz, Robert ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Behavior; Cognition; Development; Dopamine; Glutamate; Inflammation; Kynurenine; Tryptophan; 7 nicotinic receptor

Indexed keywords

EID: 84998694466     PISSN: 15697339     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-12-800981-9.00025-0     Document Type: Chapter

References (241)

1. Abazyan, B., Nomura, J., Kannan, G., Ishizuka, K., Tamashiro, K.L., Nucifora, F., et al. Prenatal interaction of mutant DISC1 and immune activation produces adult psychopathology. Biological Psychiatry 68:12 (2010), 1172–1181, 10.1016/j.biopsych.2010.09.022.
2. Akagbosu, C.O., Evans, G.C., Gulick, D., Suckow, R.F., Bucci, D.J., Exposure to kynurenic acid during adolescence produces memory deficits in adulthood. Schizophrenia Bulletin 38:4 (2012), 769–778, 10.1093/schbul/sbq151.
3. Albuquerque, E.X., Schwarcz, R., Kynurenic acid as an antagonist of alpha7 nicotinic acetylcholine receptors in the brain: facts and challenges. Biochemical Pharmacology 85:8 (2013), 1027–1032, 10.1016/j.bcp.2012.12.014 pii:S0006-2952(12)00800-3.
4. Alexander, K.S., Pocivavsek, A., Wu, H.-Q., Pershing, M.L., Schwarcz, R., Bruno, J.P., Early developmental elevations of brain kynurenic acid impair cognitive flexibility in adults: reversal with galantamine. Neuroscience 238 (2013), 19–28, 10.1016/j.neuroscience.2013.01.063.
5. Alexander, K.S., Wu, H.-Q., Schwarcz, R., Bruno, J.P., Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology 220:3 (2012), 627–637, 10.1007/s00213-011-2539-2.
6. Alkondon, M., Pereira, E.F., Yu, P., Arruda, E.Z., Almeida, L.E., Guidetti, P., et al. Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. The Journal of Neuroscience 24:19 (2004), 4635–4648, 10.1523/JNEUROSCI.5631-03.2004.
7. Amaral, M., Levy, C., Heyes, D.J., Lafite, P., Outeiro, T.F., Giorgini, F., et al. Structural basis of kynurenine 3-monooxygenase inhibition. Nature 496:7445 (2013), 382–385, 10.1038/nature12039.
8. Amori, L., Guidetti, P., Pellicciari, R., Kajii, Y., Schwarcz, R., On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. Journal of Neurochemistry 109:2 (2009), 316–325, 10.1111/j.1471-4159.2009.05893.x.
9. Amori, L., Wu, H.-Q., Marinozzi, M., Pellicciari, R., Guidetti, P., Schwarcz, R., Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159:1 (2009), 196–203, 10.1016/j.neuroscience.2008.11.055.
10. Anis, N.A., Berry, S.C., Burton, N.R., Lodge, D., The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. British Journal of Pharmacology 79:2 (1983), 565–575.
11. Aoyama, N., Takahashi, N., Saito, S., Maeno, N., Ishihara, R., Ji, X., et al. Association study between kynurenine 3-monooxygenase gene and schizophrenia in the Japanese population. Genes Brain and Behavior 5:4 (2006), 364–368, 10.1111/j.1601-183X.2006.00231.x.
12. Arion, D., Unger, T., Lewis, D.A., Levitt, P., Mirnics, K., Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biological Psychiatry 62:7 (2007), 711–721, 10.1016/j.biopsych.2006.12.021.
13. −/− mice. International Journal of Neuropsychopharmacology 13:4 (2010), 475–485, 10.1017/S1461145709990253.
14. Atlas, A., Franzen-Rohl, E., Söderlund, J., Jonsson, E.G., Samuelsson, M., Schwieler, L., et al. Sustained elevation of kynurenic Acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis. International Journal of Tryptophan Research 6 (2013), 89–96, 10.4137/IJTR.S13256.
15. Bauman, M.D., Iosif, A.M., Smith, S.E., Bregere, C., Amaral, D.G., Patterson, P.H., Activation of the maternal immune system during pregnancy alters behavioral development of rhesus monkey offspring. Biological Psychiatry 75:4 (2014), 332–341, 10.1016/j.biopsych.2013.06.025.
16. Bayer, T.A., Falkai, P., Maier, W., Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the “two hit hypothesis”. Journal of Psychiatric Research 33:6 (1999), 543–548.
17. Beal, M.F., Swartz, K.J., Isacson, O., Developmental changes in brain kynurenic acid concentrations. Developmental Brain Research 68:1 (1992), 136–139.
18. Bechter, K., Reiber, H., Herzog, S., Fuchs, D., Tumani, H., Maxeiner, H.G., Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. Journal of Psychiatric Research 44:5 (2010), 321–330, 10.1016/j.jpsychires.2009.08.008.
19. Beggiato, S., Antonelli, T., Tomasini, M.C., Tanganelli, S., Fuxe, K., Schwarcz, R., et al. Kynurenic acid, by targeting alpha7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo. European Journal of Neuroscience 37:9 (2013), 1470–1477, 10.1111/ejn.12160.
20. Beggiato, S., Sathyasaikumar, K.V., Notarangelo, F.M., Giorgini, F., Muchowski, P.J., Schwarcz, R., Prenatal kynurenine treatment in mice: effects on placental and fetal brain kynurenines. Society for Neuroscience Abstract, 39, 2014 51.05.
21. Beggiato, S., Tanganelli, S., Fuxe, K., Antonelli, T., Schwarcz, R., Ferraro, L., Endogenous kynurenic acid regulates extracellular GABA levels in the rat prefrontal cortex. Neuropharmacology 82 (2014), 11–18, 10.1016/j.neuropharm.2014.02.019.
22. Behrens, M.M., Ali, S.S., Dugan, L.L., Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia. The Journal of Neuroscience 28:51 (2008), 13957–13966, 10.1523/JNEUROSCI.4457-08.2008.
23. Bender, D.A., McCreanor, G.M., The preferred route of kynurenine metabolism in the rat. Biochimica et Biophysica Acta 717:1 (1982), 56–60.
24. Bergeron, R., Coyle, J.T., NAAG, NMDA receptor and psychosis. Current Medicinal Chemistry 19:9 (2012), 1360–1364.
25. Bergersen, L.H., Morland, C., Ormel, L., Rinholm, J.E., Larsson, M., Wold, J.F., et al. Immunogold detection of L-glutamate and D-serine in small synaptic-like microvesicles in adult hippocampal astrocytes. Cerebral Cortex 22:7 (2012), 1690–1697, 10.1093/cercor/bhr254.
26. Bergink, V., Gibney, S.M., Drexhage, H.A., Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biological Psychiatry 75:4 (2014), 324–331, 10.1016/j.biopsych.2013.09.037.
27. 2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS One, 8(11), 2013, e82180, 10.1371/journal.pone.0082180.
28. Birch, P.J., Grossman, C.J., Hayes, A.G., Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. European Journal of Pharmacology 154:1 (1988), 85–87.
29. Blanco Ayala, T., Lugo Huitron, R., Carmona Aparicio, L., Ramirez Ortega, D., Gonzalez Esquivel, D., Pedraza Chaverri, J., Perez de la Cruz, G., Rios, C., Schwarcz, R., Perez de la Cruz, V., et al. Alternative kynurenic acid synthesis routes studied in the rat cerebellum. Frontiers in Cell Neuroscience, 9, 2015, 178, 10.3389/fncel.2015.00178.
30. Borovcanin, M., Jovanovic, I., Radosavljevic, G., Djukic Dejanovic, S., Bankovic, D., Arsenijevic, N., et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. Journal of Psychiatric Research 46:11 (2012), 1421–1426, 10.1016/j.jpsychires.2012.08.016.
31. Bouzier-Sore, A.K., Pellerin, L., Unraveling the complex metabolic nature of astrocytes. Frontiers in Cellular Neuroscience, 7, 2013, 179, 10.3389/fncel.2013.00179.
32. Brown, A.S., The environment and susceptibility to schizophrenia. Progress in Neurobiology 93:1 (2011), 23–58, 10.1016/j.pneurobio.2010.09.003.
33. Brown, A.S., Susser, E.S., In utero infection and adult schizophrenia. Mental Retardation and Developmental Disabilities Research Reviews 8:1 (2002), 51–57, 10.1002/mrdd.10004.
34. Busse, S., Busse, M., Schiltz, K., Bielau, H., Gos, T., Brisch, R., et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?. Brain Behavior and Immunity 26:8 (2012), 1273–1279, 10.1016/j.bbi.2012.08.005.
35. Cannazza, G., Chiarugi, A., Parenti, C., Zanoli, P., Baraldi, M., Changes in kynurenic, anthranilic, and quinolinic acid concentrations in rat brain tissue during development. Neurochemical Research 26:5 (2001), 511–514.
36. Carlsson, M., Carlsson, A., Schizophrenia: a subcortical neurotransmitter imbalance syndrome?. Schizophrenia Bulletin 16:3 (1990), 425–432.
37. Carlsson, M.L., Carlsson, A., Nilsson, M., Schizophrenia: from dopamine to glutamate and back. Current Medicinal Chemistry 11:3 (2004), 267–277.
38. Carpenedo, R., Chiarugi, A., Russi, P., Lombardi, G., Carlà, V., Pellicciari, R., et al. Inhibitors of kynurenine hydroxylase and kynureninase increase cerebral formation of kynurenate and have sedative and anticonvulsant activities. Neuroscience 61:2 (1994), 237–243.
39. Carpenedo, R., Pittaluga, A., Cozzi, A., Attucci, S., Galli, A., Raiteri, M., et al. Presynaptic kynurenate-sensitive receptors inhibit glutamate release. European Journal of Neuroscience 13:11 (2001), 2141–2147.
40. Ceresoli-Borroni, G., Rassoulpour, A., Wu, H.-Q., Guidetti, P., Schwarcz, R., Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. Journal of Neural Transmission 113:10 (2006), 1355–1365, 10.1007/s00702-005-0432-z.
41. Ceresoli-Borroni, G., Schwarcz, R., Perinatal kynurenine pathway metabolism in the normal and asphyctic rat brain. Amino Acids 19:1 (2000), 311–323.
42. Chess, A.C., Landers, A.M., Bucci, D.J., L-kynurenine treatment alters contextual fear conditioning and context discrimination but not cue-specific fear conditioning. Behavioural Brain Research 201:2 (2009), 325–331, 10.1016/j.bbr.2009.03.013.
43. Chess, A.C., Simoni, M.K., Alling, T.E., Bucci, D.J., Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophrenia Bulletin 33:3 (2007), 797–804, 10.1093/schbul/sbl033.
44. Chiappelli, J., Pocivavsek, A., Nugent, K.L., Notarangelo, F.M., Kochunov, P., Rowland, L.M., et al. Stress-induced increase in kynurenic acid as a potential biomarker for patients with schizophrenia and distress intolerance. JAMA Psychiatry 71:7 (2014), 761–768, 10.1001/jamapsychiatry.2014.243.
45. Chiarugi, A., Moroni, F., Quinolinic acid formation in immune-activated mice: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(-3-nitrophenyl)thiazol-2yl]-benzenesul fonamide (Ro 61-8048), two potent and selective inhibitors of kynurenine hydroxylase. Neuropharmacology 38:8 (1999), 1225–1233.
46. Chittiprol, S., Venkatasubramanian, G., Neelakantachar, N., Allha, N., Shetty, K.T., Gangadhar, B.N., Beta2-microglobulin abnormalities in antipsychotic-naive schizophrenia: evidence for immune pathogenesis. Brain Behavior and Immunity 23:2 (2009), 189–192, 10.1016/j.bbi.2008.08.007.
47. Clarke, L.E., Barres, B.A., Emerging roles of astrocytes in neural circuit development. Nature Reviews Neuroscience 14:5 (2013), 311–321, 10.1038/nrn3484.
48. Conti, F., DeBiasi, S., Minelli, A., Melone, M., Expression of NR1 and NR2A/B subunits of the NMDA receptor in cortical astrocytes. Glia 17:3 (1996), 254–258, 10.1002/(SICI)1098-1136(199607)17 3<254::AID-GLIA7>3.0.CO;2–0.
49. Cooper, A.J., The role of glutamine transaminase K (GTK) in sulfur and alpha-keto acid metabolism in the brain, and in the possible bioactivation of neurotoxicants. Neurochemistry International 44:8 (2004), 557–577, 10.1016/j.neuint.2003.12.002.
50. Coyle, J.T., The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Review of Psychiatry 3:5 (1996), 241–253.
51. Coyle, J.T., NMDA receptor and schizophrenia: a brief history. Schizophrenia Bulletin 38:5 (2012), 920–926, 10.1093/schbul/sbs076.
52. Coyle, J.T., Basu, A., Benneyworth, M., Balu, D., Konopaske, G., Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications. Handbook of Experimental Pharmacology 213 (2012), 267–295, 10.1007/978-3-642-25758-2_10.
53. DeAngeli, N.E., Todd, T.P., Chang, S.E., Yeh, H.H., Yeh, P.W., Bucci, D.J., Exposure to kynurenic acid during adolescence increases sign-tracking and impairs long-term potentiation in adulthood. Frontiers in Behavioral Neuroscience, 8, 2014, 451, 10.3389/fnbeh.2014.00451.
54. DiNatale, B.C., Murray, I.A., Schroeder, J.C., Flaveny, C.A., Lahoti, T.S., Laurenzana, E.M., et al. Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicological Sciences 115:1 (2010), 89–97, 10.1093/toxsci/kfq024.
55. Dounay, A.B., Anderson, M., Bechle, B.M., Campbell, B.M., Claffey, M.M., Evdokimov, A., et al. Discovery of brain-penetrant, irreversible kynurenine aminotransferase II inhibitors for schizophrenia. ACS Medicinal Chemistry Letters 3:3 (2012), 187–192, 10.1021/ml200204m.
56. Duffy, A.M., Fitzgerald, M.L., Chan, J., Robinson, D.C., Milner, T.A., Mackie, K., et al. Acetylcholine alpha7 nicotinic and dopamine D2 receptors are targeted to many of the same postsynaptic dendrites and astrocytes in the rodent prefrontal cortex. Synapse 65:12 (2011), 1350–1367, 10.1002/syn.20977.
57. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L.H., Engberg, G., Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neuroscience Letters 313:1–2 (2001), 96–98.
58. Erhardt, S., Schwieler, L., Emanuelsson, C., Geyer, M., Endogenous kynurenic acid disrupts prepulse inhibition. Biological Psychiatry 56:4 (2004), 255–260, 10.1016/j.biopsych.2004.06.006.
59. Fatemi, S.H., Earle, J., Kanodia, R., Kist, D., Emamian, E.S., Patterson, P.H., et al. Prenatal viral infection leads to pyramidal cell atrophy and macrocephaly in adulthood: implications for genesis of autism and schizophrenia. Cellular and Molecular Neurobiology 22:1 (2002), 25–33.
60. Forrest, C.M., Khalil, O.S., Pisar, M., Darlington, L.G., Stone, T.W., Prenatal inhibition of the tryptophan-kynurenine pathway alters synaptic plasticity and protein expression in the rat hippocampus. Brain Research 1504 (2013), 1–15, 10.1016/j.brainres.2013.01.031.
61. Forrest, C.M., Khalil, O.S., Pisar, M., McNair, K., Kornisiuk, E., Snitcofsky, M., et al. Changes in synaptic transmission and protein expression in the brains of adult offspring after prenatal inhibition of the kynurenine pathway. Neuroscience 254 (2013), 241–259, 10.1016/j.neuroscience.2013.09.034.
62. Fortier, M.E., Luheshi, G.N., Boksa, P., Effects of prenatal infection on prepulse inhibition in the rat depend on the nature of the infectious agent and the stage of pregnancy. Behavioural Brain Research 181:2 (2007), 270–277, 10.1016/j.bbr.2007.04.016.
63. Foster, A.C., Vezzani, A., French, E.D., Schwarcz, R., Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neuroscience Letters 48:3 (1984), 273–278.
64. Fukui, S., Schwarcz, R., Rapoport, S.I., Takada, Y., Smith, Q.R., Blood–brain barrier transport of kynurenines: implications for brain synthesis and metabolism. Journal of Neurochemistry 56:6 (1991), 2007–2017.
65. Fukuwatari, T., Sekine, A., Higashiyama, S., Sano, M., Shibata, K., High leucine and lysine diet shows additive effects on suppression of kynurenic acid production in rat brain. Society for Neuroscience Abstract, 38, 2013 152.16.
66. Gál, E.M., Sherman, A.D., Synthesis and metabolism of L-kynurenine in rat brain. Journal of Neurochemistry 30:3 (1978), 607–613.
67. Gál, E.M., Young, R.B., Sherman, A.D., Tryptophan loading: consequent effects on the synthesis of kynurenine and 5-hydroxyindoles in rat brain. Journal of Neurochemistry 31:1 (1978), 237–244.
68. Ganong, A.H., Lanthorn, T.H., Cotman, C.W., Kynurenic acid inhibits synaptic and acidic amino acid-induced responses in the rat hippocampus and spinal cord. Brain Research 273:1 (1983), 170–174.
69. Gehl, L.M., Saab, O.H., Bzdega, T., Wroblewska, B., Neale, J.H., Biosynthesis of NAAG by an enzyme-mediated process in rat central nervous system neurons and glia. Journal of Neurochemistry 90:4 (2004), 989–997, 10.1111/j.1471-4159.2004.02578.x.
70. Giorgini, F., Huang, S.Y., Sathyasaikumar, K.V., Notarangelo, F.M., Thomas, M.A., Tararina, M., et al. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. Journal of Biological Chemistry 288:51 (2013), 36554–36566, 10.1074/jbc.M113.503813.
71. Giovanoli, S., Engler, H., Engler, A., Richetto, J., Voget, M., Willi, R., et al. Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice. Science 339:6123 (2013), 1095–1099, 10.1126/science.1228261.
72. Gold, J.M., Cognitive deficits as treatment targets in schizophrenia. Schizophrenia Research 72:1 (2004), 21–28, 10.1016/j.schres.2004.09.008.
73. Gonzalez-Burgos, G., Lewis, D.A., NMDA receptor hypofunction, parvalbumin-positive neurons, and cortical gamma oscillations in schizophrenia. Schizophrenia Bulletin 38:5 (2012), 950–957, 10.1093/schbul/sbs010.
74. Gramsbergen, J.B., Hodgkins, P.S., Rassoulpour, A., Turski, W.A., Guidetti, P., Schwarcz, R., Brain-specific modulation of kynurenic acid synthesis in the rat. Journal of Neurochemistry 69:1 (1997), 290–298.
75. Green, A.R., Curzon, G., The effect of tryptophan metabolites on brain 5-hydroxytryptamine metabolism. Biochemical Pharmacology 19:6 (1970), 2061–2068.
76. Green, M.F., Nuechterlein, K.H., Kern, R.S., Baade, L.E., Fenton, W.S., Gold, J.M., et al. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS psychometric and standardization study. American Journal of Psychiatry 165:2 (2008), 221–228, 10.1176/appi.ajp.2007.07010089.
77. Guidetti, P., Amori, L., Sapko, M.T., Okuno, E., Schwarcz, R., Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. Journal of Neurochemistry 102:1 (2007), 103–111, 10.1111/j.1471-4159.2007.04556.x.
78. Guidetti, P., Hoffman, G.E., Melendez-Ferro, M., Albuquerque, E.X., Schwarcz, R., Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia 55:1 (2007), 78–92, 10.1002/glia.20432.
79. Guidetti, P., Okuno, E., Schwarcz, R., Characterization of rat brain kynurenine aminotransferases I and II. Journal of Neuroscience Research 50:3 (1997), 457–465.
80. Guidetti, P., Schwarcz, R., Determination of alpha-aminoadipic acid in brain, peripheral tissues, and body fluids using GC/MS with negative chemical ionization. Molecular Brain Research 118:1–2 (2003), 132–139.
81. Guillemin, G.J., Cullen, K.M., Lim, C.K., Smythe, G.A., Garner, B., Kapoor, V., et al. Characterization of the kynurenine pathway in human neurons. The Journal of Neuroscience 27:47 (2007), 12884–12892, 10.1523/JNEUROSCI.4101-07.2007.
82. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Smith, D.G., Kapoor, V., Armati, P.J., et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. Journal of Neurochemistry 78:4 (2001), 842–853.
83. Han, Q., Cai, T., Tagle, D.A., Robinson, H., Li, J., Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Bioscience Reports 28:4 (2008), 205–215, 10.1042/BSR20080085.
84. Han, Q., Robinson, H., Li, J., Crystal structure of human kynurenine aminotransferase II. Journal of Biological Chemistry 283:6 (2008), 3567–3573, 10.1074/jbc.M708358200.
85. Heinrichs, R.W., The primacy of cognition in schizophrenia. American Psychologist 60:3 (2005), 229–242, 10.1037/0003-066X.60.3.229.
86. Heyes, M.P., Achim, C.L., Wiley, C.A., Major, E.O., Saito, K., Markey, S.P., Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochemical Journal 320:Pt 2 (1996), 595–597.
87. Heyes, M.P., Brew, B.J., Saito, K., Quearry, B.J., Price, R.W., Lee, K., et al. Inter-relationships between quinolinic acid, neuroactive kynurenines, neopterin and beta 2-microglobulin in cerebrospinal fluid and serum of HIV-1-infected patients. Journal of Neuroimmunology 40:1 (1992), 71–80.
88. Heyes, M.P., Saito, K., Crowley, J.S., Davis, L.E., Demitrack, M.A., Der, M., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:Pt 5 (1992), 1249–1273.
89. Hightower, B.G., Rodefer, J.S., Investigation of kynurenic acid as a possible biomarker for cognitive impairment associated with schizophrenia. Society for Neuroscience Abstract, 36, 2011 163.19.
90. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E.X., The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. The Journal of Neuroscience 21:19 (2001), 7463–7473.
91. Hodgkins, P.S., Schwarcz, R., Interference with cellular energy metabolism reduces kynurenic acid formation in rat brain slices: reversal by lactate and pyruvate. European Journal of Neuroscience 10:6 (1998), 1986–1994.
92. Hodgkins, P.S., Wu, H.-Q., Zielke, H.R., Schwarcz, R., 2-Oxoacids regulate kynurenic acid production in the rat brain: studies in vitro and in vivo. Journal of Neurochemistry 72:2 (1999), 643–651.
93. Holtze, M., Asp, L., Schwieler, L., Engberg, G., Karlsson, H., Induction of the kynurenine pathway by neurotropic influenza A virus infection. Journal of Neuroscience Research 86:16 (2008), 3674–3683, 10.1002/jnr.21799.
94. Holtze, M., Saetre, P., Engberg, G., Schwieler, L., Werge, T., Andreassen, O.A., et al. Kynurenine 3-monooxygenase polymorphisms: relevance for kynurenic acid synthesis in patients with schizophrenia and healthy controls. Journal of Psychiatry and Neuroscience 37:1 (2012), 53–57, 10.1503/jpn.100175.
95. Hornig, M., Lipkin, W.I., Infectious and immune factors in the pathogenesis of neurodevelopmental disorders: epidemiology, hypotheses, and animal models. Mental Retardation and Developmental Disabilities Research Reviews 7:3 (2001), 200–210, 10.1002/mrdd.1028.
96. Iaccarino, H.F., Suckow, R.F., Xie, S., Bucci, D.J., The effect of transient increases in kynurenic acid and quinolinic acid levels early in life on behavior in adulthood: Implications for schizophrenia. Schizophrenia Research 150:2–3 (2013), 392–397, 10.1016/j.schres.2013.09.004.
97. Ishii, K., Iizuka, H., Ogaya, T., Song, Z., Fukushima, T., Comparative study on kynurenic acid production in the rat striatum by tryptophan enantiomers: an in vivo microdialysis study. Chirality 23:Suppl. 1 (2011), E12–E15, 10.1002/chir.20938.
98. Javitt, D.C., Zukin, S.R., Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 148:10 (1991), 1301–1308.
99. Johansson, A.S., Owe-Larsson, B., Asp, L., Kocki, T., Adler, M., Hetta, J., et al. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. Journal of Psychiatric Research 47:11 (2013), 1815–1823, 10.1016/j.jpsychires.2013.08.008.
100. Joseph, M.H., Determination of kynurenine by a simple gas-liquid chromatographic method applicable to urine, plasma, brain and cerebrospinal fluid. Journal of Chromatography 146:1 (1978), 33–41.
101. Katsel, P., Byne, W., Roussos, P., Tan, W., Siever, L., Haroutunian, V., Astrocyte and glutamate markers in the superficial, deep, and white matter layers of the anterior cingulate gyrus in schizophrenia. Neuropsychopharmacology 36:6 (2011), 1171–1177, 10.1038/npp.2010.252.
102. Kessler, M., Terramani, T., Lynch, G., Baudry, M., A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. Journal of Neurochemistry 52:4 (1989), 1319–1328.
103. Khalil, O.S., Pisar, M., Forrest, C.M., Vincenten, M.C., Darlington, L.G., Stone, T.W., Prenatal inhibition of the kynurenine pathway leads to structural changes in the hippocampus of adult rat offspring. European Journal of Neuroscience 39:10 (2014), 1558–1571, 10.1111/ejn.12535.
104. Khan, Z.U., Koulen, P., Rubinstein, M., Grandy, D.K., Goldman-Rakic, P.S., An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America 98:4 (2001), 1964–1969, 10.1073/pnas.98.4.1964.
105. Kiank, C., Zeden, J.P., Drude, S., Domanska, G., Fusch, G., Otten, W., et al. Psychological stress-induced, IDO1-dependent tryptophan catabolism: implications on immunosuppression in mice and humans. PLoS One, 5(7), 2010, e11825, 10.1371/journal.pone.0011825.
106. Kolodkin-Gal, I., Romero, D., Cao, S., Clardy, J., Kolter, R., Losick, R., D-amino acids trigger biofilm disassembly. Science 328:5978 (2010), 627–629, 10.1126/science.1188628.
107. Konradsson-Geuken, A., Wu, H.-Q., Gash, C.R., Alexander, K.S., Campbell, A., Sozeri, Y., et al. Cortical kynurenic acid bi-directionally modulates prefrontal glutamate levels as assessed by microdialysis and rapid electrochemistry. Neuroscience 169:4 (2010), 1848–1859, 10.1016/j.neuroscience.2010.05.052.
108. Koshy Cherian, A., Gritton, H., Johnson, D.E., Young, D., Kozak, R., Sarter, M., A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology 82 (2014), 41–48, 10.1016/j.neuropharm.2014.03.004.
109. Kozak, R., Campbell, B.M., Strick, C.A., Horner, W., Hoffmann, W.E., Kiss, T., et al. Reduction of brain kynurenic acid improves cognitive function. The Journal of Neuroscience 34:32 (2014), 10592–10602, 10.1523/JNEUROSCI.1107-14.2014.
110. Krystal, J.H., Karper, L.P., Seibyl, J.P., Freeman, G.K., Delaney, R., Bremner, J.D., et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 51:3 (1994), 199–214.
111. Lahti, A.C., Koffel, B., LaPorte, D., Tamminga, C.A., Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:1 (1995), 9–19, 10.1016/0893-133X(94)00131-I.
112. Lam, H., Oh, D.C., Cava, F., Takacs, C.N., Clardy, J., de Pedro, M.A., et al. D-amino acids govern stationary phase cell wall remodeling in bacteria. Science 325:5947 (2009), 1552–1555, 10.1126/science.1178123.
113. Lapin, I.P., Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice. Journal of Neural Transmission 42:1 (1978), 37–43.
114. Laugeray, A., Launay, J.M., Callebert, J., Surget, A., Belzung, C., Barone, P.R., Peripheral and cerebral metabolic abnormalities of the tryptophan-kynurenine pathway in a murine model of major depression. Behavioural Brain Research 210:1 (2010), 84–91, 10.1016/j.bbr.2010.02.014.
115. Leklem, J.E., Quantitative aspects of tryptophan metabolism in humans and other species: a review. American Journal of Clinical Nutrition 24:6 (1971), 659–672.
116. Leonard, S., Adams, C., Breese, C.R., Adler, L.E., Bickford, P., Byerley, W., et al. Nicotinic receptor function in schizophrenia. Schizophrenia Bulletin 22:3 (1996), 431–445.
117. Levin, E.D., Nicotinic receptor subtypes and cognitive function. Journal of Neurobiology 53:4 (2002), 633–640, 10.1002/neu.10151.
118. Linderholm, K.R., Skogh, E., Olsson, S.K., Dahl, M.L., Holtze, M., Engberg, G., et al. Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophrenia Bulletin 38:3 (2012), 426–432, 10.1093/schbul/sbq086.
119. Liu, X.C., Holtze, M., Powell, S.B., Terrando, N., Larsson, M.K., Persson, A., et al. Behavioral disturbances in adult mice following neonatal virus infection or kynurenine treatment–role of brain kynurenic acid. Brain Behavior and Immunity 36 (2014), 80–89, 10.1016/j.bbi.2013.10.010.
120. Lopes, C., Pereira, E.F., Wu, H.-Q., Purushottamachar, P., Njar, V., Schwarcz, R., et al. Competitive antagonism between the nicotinic allosteric potentiating ligand galantamine and kynurenic acid at alpha7∗ nicotinic receptors. Journal of Pharmacology and Experimental Therapeutics 322:1 (2007), 48–58, 10.1124/jpet.107.123109.
121. Luby, E.D., Cohen, B.D., Rosenbaum, G., Gottlieb, J.S., Kelley, R., Study of a new schizophrenomimetic drug; sernyl. AMA Archives of Neurology and Psychiatry 81:3 (1959), 363–369.
122. Luccini, E., Musante, V., Neri, E., Raiteri, M., Pittaluga, A., N-methyl-D-aspartate autoreceptors respond to low and high agonist concentrations by facilitating, respectively, exocytosis and carrier-mediated release of glutamate in rat hippocampus. Journal of Neuroscience Research 85:16 (2007), 3657–3665, 10.1002/jnr.21446.
123. Lugo-Huitron, R., Blanco-Ayala, T., Ugalde-Muniz, P., Carrillo-Mora, P., Pedraza-Chaverri, J., Silva-Adaya, D., et al. On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicology and Teratology 33:5 (2011), 538–547, 10.1016/j.ntt.2011.07.002.
124. Malik, S.S., Patterson, D.N., Ncube, Z., Toth, E.A., The crystal structure of human quinolinic acid phosphoribosyltransferase in complex with its inhibitor phthalic acid. Proteins 82:3 (2014), 405–414, 10.1002/prot.24406.
125. Manuelpillai, U., Ligam, P., Smythe, G., Wallace, E.M., Hirst, J., Walker, D.W., Identification of kynurenine pathway enzyme mRNAs and metabolites in human placenta: up-regulation by inflammatory stimuli and with clinical infection. American Journal of Obstetrics and Gynecology 192:1 (2005), 280–288, 10.1016/j.ajog.2004.06.090.
126. Markham, J.A., Koenig, J.I., Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology (Berl) 214:1 (2011), 89–106, 10.1007/s00213-010-2035-0.
127. Martineau, M., Shi, T., Puyal, J., Knolhoff, A.M., Dulong, J., Gasnier, B., et al. Storage and uptake of D-serine into astrocytic synaptic-like vesicles specify gliotransmission. The Journal of Neuroscience 33:8 (2013), 3413–3423, 10.1523/JNEUROSCI.3497-12.2013.
128. Matute, C., Melone, M., Vallejo-Illarramendi, A., Conti, F., Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 49:3 (2005), 451–455, 10.1002/glia.20119.
129. McAllister, A.K., Major histocompatibility complex I in brain development and schizophrenia. Biological Psychiatry 75:4 (2014), 262–268, 10.1016/j.biopsych.2013.10.003.
130. McKibbin, C.L., Brekke, J.S., Sires, D., Jeste, D.V., Patterson, T.L., Direct assessment of functional abilities: relevance to persons with schizophrenia. Schizophrenia Research 72:1 (2004), 53–67, 10.1016/j.schres.2004.09.011.
131. Meng, B., Wu, D., Gu, J., Ouyang, S., Ding, W., Liu, Z.J., Structural and functional analyses of human tryptophan 2,3-dioxygenase. Proteins 82:11 (2014), 3210–3216, 10.1002/prot.24653.
132. Meyer, U., Feldon, J., Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacology 206:4 (2009), 587–602, 10.1007/s00213-009-1504-9.
133. Michel, M., Schmidt, M.J., Mirnics, K., Immune system gene dysregulation in autism and schizophrenia. Developmental Neurobiology 72:10 (2012), 1277–1287, 10.1002/dneu.22044.
134. Miller, C.L., Llenos, I.C., Dulay, J.R., Barillo, M.M., Yolken, R.H., Weis, S., Expression of the kynurenine pathway enzyme tryptophan 2,3-dioxygenase is increased in the frontal cortex of individuals with schizophrenia. Neurobiology of Disease 15:3 (2004), 618–629, 10.1016/j.nbd.2003.12.015.
135. Miller, C.L., Llenos, I.C., Dulay, J.R., Weis, S., Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder. Brain Research 1073–1074 (2006), 25–37, 10.1016/j.brainres.2005.12.056.
136. Miura, H., Shirokawa, T., Isobe, K., Ozaki, N., Shifting the balance of brain tryptophan metabolism elicited by isolation housing and systemic administration of lipopolysaccharide in mice. Stress 12:3 (2009), 206–214, 10.1080/10253890802252442.
137. Moroni, F., Russi, P., Lombardi, G., Beni, M., Carlà, V., Presence of kynurenic acid in the mammalian brain. Journal of Neurochemistry 51:1 (1988), 177–180.
138. Nawa, H., Takahashi, M., Patterson, P.H., Cytokine and growth factor involvement in schizophrenia–support for the developmental model. Molecular Psychiatry 5:6 (2000), 594–603.
139. Nicholls, T., Nitsos, I., Smythe, G., Walker, D.W., Kynurenine production and catabolism in fetal sheep with embolized or nonembolized placentas. American Journal of Obstetrics and Gynecology 185:4 (2001), 988–995, 10.1067/mob.2001.117969.
140. Nilsson, L.K., Linderholm, K.R., Engberg, G., Paulson, L., Blennow, K., Lindstrom, L.H., et al. Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophrenia Research 80:2–3 (2005), 315–322, 10.1016/j.schres.2005.07.013.
141. Nilsson, L.K., Linderholm, K.R., Erhardt, S., Subchronic treatment with kynurenine and probenecid: effects on prepulse inhibition and firing of midbrain dopamine neurons. Journal of Neural Transmission 113:5 (2006), 557–571, 10.1007/s00702-005-0343-z.
142. Notarangelo, F.M., Schwarcz, R., Restraint stress during pregnancy raises kynurenic acid levels in placenta and fetal brain. Society for Neuroscience Abstract, 39, 2014 348.16.
143. Notarangelo, F.M., Wang, X.-D., Horning, K.J., Schwarcz, R., Role of D-amino acid oxidase in the production of kynurenine pathway metabolites from D-tryptophan in mice. Society for Neuroscience-Abstracts, 38, 2013 344.307.
144. Notarangelo, F.M., Wilson, E.H., Horning, K.J., Thomas, M.A., Harris, T.H., Fang, Q., et al. Evaluation of kynurenine pathway metabolism in Toxoplasma gondii-infected mice: implications for schizophrenia. Schizophrenia Research 152:1 (2014), 261–267, 10.1016/j.schres.2013.11.011.
145. Nuechterlein, K.H., Barch, D.M., Gold, J.M., Goldberg, T.E., Green, M.F., Heaton, R.K., Identification of separable cognitive factors in schizophrenia. Schizophrenia Research 72:1 (2004), 29–39, 10.1016/j.schres.2004.09.007.
146. Okuno, E., Nakamura, M., Schwarcz, R., Two kynurenine aminotransferases in human brain. Brain Research 542:2 (1991), 307–312.
147. Olney, J.W., Newcomer, J.W., Farber, N.B., NMDA receptor hypofunction model of schizophrenia. Journal of Psychiatric Research 33:6 (1999), 523–533.
148. Olsson, S.K., Larsson, M.K., Erhardt, S., Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. Journal of Neural Transmission 119:2 (2012), 155–163, 10.1007/s00702-011-0706-6.
149. van Os, J., Selten, J.P., Prenatal exposure to maternal stress and subsequent schizophrenia. The May 1940 invasion of The Netherlands. British Journal of Psychiatry 172 (1998), 324–326.
150. Owe-Young, R., Webster, N.L., Mukhtar, M., Pomerantz, R.J., Smythe, G., Walker, D., et al. Kynurenine pathway metabolism in human blood-brain-barrier cells: implications for immune tolerance and neurotoxicity. Journal of Neurochemistry 105:4 (2008), 1346–1357, 10.1111/j.1471-4159.2008.05241.x.
151. Pawlak, D., Takada, Y., Urano, T., Takada, A., Serotonergic and kynurenic pathways in rats exposed to foot shock. Brain Research Bulletin 52:3 (2000), 197–205.
152. Pellicciari, R., Rizzo, R.C., Costantino, G., Marinozzi, M., Amori, L., Guidetti, P., et al. Modulators of the kynurenine pathway of tryptophan metabolism: synthesis and preliminary biological evaluation of (S)-4-(ethylsulfonyl)benzoylalanine, a potent and selective kynurenine aminotransferase II (KAT II) inhibitor. ChemMedChem 1:5 (2006), 528–531, 10.1002/cmdc.200500095.
153. Pellicciari, R., Venturoni, F., Bellocchi, D., Carotti, A., Marinozzi, M., Macchiarulo, A., et al. Sequence variants in kynurenine aminotransferase II (KAT II) orthologs determine different potencies of the inhibitor S-ESBA. ChemMedChem 3:8 (2008), 1199–1202, 10.1002/cmdc.200800109.
154. Perea, G., Navarrete, M., Araque, A., Tripartite synapses: astrocytes process and control synaptic information. Trends in Neuroscience 32:8 (2009), 421–431, 10.1016/j.tins.2009.05.001.
155. Perkins, M.N., Stone, T.W., An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Research 247:1 (1982), 184–187.
156. Pershing, M.L., Bortz, D.M., Pocivavsek, A., Fredericks, P.J., Jorgensen, C.V., Vunck, S.A., et al. Elevated levels of kynurenic acid during gestation produce neurochemical, morphological, and cognitive deficits in adulthood: implications for schizophrenia. Neuropharmacology 90 (2015), 33–41, 10.1016/j.neuropharm.2014.10.017.
157. Pershing, M.L., Lindquist, D.H., Pocivavsek, A., Tseng, K.Y., Schwarcz, R., Bruno, J.P., Prenatal kynurenine exposure alters maturation of the conditioned fear response: normalization with an alpha7nAChR partial agonist. Society for Neuroscience Abstract, 36, 2014 51.09.
158. Phenis, D., Vunck, S.A., Schwarcz, R., Bruno, J.P., Acute elevations of brain kynurenic acid induce working memory deficits: relative contributions of alpha7 nicotinic and NMDA receptor activity. Society for Neuroscience Abstract, 39, 2014 51.10.
159. Phillips, R.S., Structure and mechanism of kynureninase. Archives of Biochemistry and Biophysics 544 (2014), 69–74, 10.1016/j.abb.2013.10.020.
160. Piontkewitz, Y., Arad, M., Weiner, I., Tracing the development of psychosis and its prevention: what can be learned from animal models. Neuropharmacology 62:3 (2012), 1273–1289, 10.1016/j.neuropharm.2011.04.019.
161. Pisar, M., Forrest, C.M., Khalil, O.S., McNair, K., Vincenten, M.C., Qasem, S., et al. Modified neocortical and cerebellar protein expression and morphology in adult rats following prenatal inhibition of the kynurenine pathway. Brain Research 1576 (2014), 1–17, 10.1016/j.brainres.2014.06.016.
162. Pocivavsek, A., Thomas, M.A., Elmer, G.I., Bruno, J.P., Schwarcz, R., Continuous kynurenine administration during the prenatal period, but not during adolescence, causes learning and memory deficits in adult rats. Psychopharmacology 231:14 (2014), 2799–2809, 10.1007/s00213-014-3452-2.
163. Pocivavsek, A., Wu, H.-Q., Okuyama, M., Kajii, Y., Elmer, G.I., Bruno, J.P., The systemically active kynurenine aminotransferase II inhibitor BFF816 attenuates contextual memory deficit induced by chronic prenatal kynurenine elevation in rats. Society for Neuroscience Abstract, 39, 2014 707.07.
164. Pocivavsek, A., Wu, H.-Q., Elmer, G.I., Bruno, J.P., Schwarcz, R., Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. European Journal of Neuroscience 35:10 (2012), 1605–1612, 10.1111/j.1460-9568.2012.08064.x.
165. Pocivavsek, A., Wu, H.-Q., Potter, M.C., Elmer, G.I., Pellicciari, R., Schwarcz, R., Fluctuations in endogenous kynurenic acid control hippocampal glutamate and memory. Neuropsychopharmacology 36:11 (2011), 2357–2367, 10.1038/npp.2011.127.
166. Poeggeler, B., Rassoulpour, A., Guidetti, P., Wu, H.-Q., Schwarcz, R., Dopaminergic control of kynurenate levels and N-methyl-D-aspartate toxicity in the developing rat striatum. Developmental Neuroscience 20:2–3 (1998), 146–153.
167. Poels, E.M., Kegeles, L.S., Kantrowitz, J.T., Slifstein, M., Javitt, D.C., Lieberman, J.A., et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Molecular Psychiatry 19:1 (2014), 20–29, 10.1038/mp.2013.136.
168. Potter, M.C., Elmer, G.I., Bergeron, R., Albuquerque, E.X., Guidetti, P., Wu, H.-Q., et al. Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology 35:8 (2010), 1734–1742, 10.1038/npp.2010.39.
169. Prescott, C., Weeks, A.M., Staley, K.J., Partin, K.M., Kynurenic acid has a dual action on AMPA receptor responses. Neuroscience Letters 402:1–2 (2006), 108–112, 10.1016/j.neulet.2006.03.051.
170. Rafice, S.A., Chauhan, N., Efimov, I., Basran, J., Raven, E.L., Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochemical Society Transactions 37:Pt 2 (2009), 408–412, 10.1042/BST0370408.
171. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Molecular Psychiatry 15:4 (2010), 393–403, 10.1038/mp.2009.116.
172. Rapoport, J.L., Giedd, J.N., Gogtay, N., Neurodevelopmental model of schizophrenia: update 2012. Molecular Psychiatry 17:12 (2012), 1228–1238, 10.1038/mp.2012.23.
173. Rassoulpour, A., Wu, H.-Q., Albuquerque, E.X., Schwarcz, R., Prolonged nicotine administration results in biphasic, brain-specific changes in kynurenate levels in the rat. Neuropsychopharmacology 30:4 (2005), 697–704, 10.1038/sj.npp.1300583.
174. Rassoulpour, A., Wu, H.-Q., Ferré, S., Schwarcz, R., Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. Journal of Neurochemistry 93:3 (2005), 762–765, 10.1111/j.1471-4159.2005.03134.x.
175. Rassoulpour, A., Wu, H.-Q., Poeggeler, B., Schwarcz, R., Systemic D-amphetamine administration causes a reduction of kynurenic acid levels in rat brain. Brain Research 802:1–2 (1998), 111–118.
176. Reinhard, J.F. Jr., Erickson, J.B., Flanagan, E.M., Quinolinic acid in neurological disease: opportunities for novel drug discovery. Advances in Pharmacology 30 (1994), 85–127.
177. Rossi, F., Han, Q., Li, J., Li, J., Rizzi, M., Crystal structure of human kynurenine aminotransferase I. Journal of Biological Chemistry 279:48 (2004), 50214–50220, 10.1074/jbc.M409291200.
178. Rossi, F., Valentina, C., Garavaglia, S., Sathyasaikumar, K.V., Schwarcz, R., Kojima, S., et al. Crystal structure-based selective targeting of the pyridoxal 5’-phosphate dependent enzyme kynurenine aminotransferase II for cognitive enhancement. Journal of Medicinal Chemistry 53:15 (2010), 5684–5689, 10.1021/jm100464k.
179. Röver, S., Cesura, A.M., Huguenin, P., Kettler, R., Szente, A., Synthesis and biochemical evaluation of N-(4-phenylthiazol-2-yl)benzenesulfonamides as high-affinity inhibitors of kynurenine 3-hydroxylase. Journal of Medicinal Chemistry 40:26 (1997), 4378–4385, 10.1021/jm970467t.
180. Saetre, P., Emilsson, L., Axelsson, E., Kreuger, J., Lindholm, E., Jazin, E., Inflammation-related genes up-regulated in schizophrenia brains. BMC Psychiatry, 7, 2007, 46, 10.1186/1471-244X-7-46.
181. Saito, K., Markey, S.P., Heyes, M.P., Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice. Brain Research 546:1 (1991), 151–154.
182. Saito, K., Markey, S.P., Heyes, M.P., Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 51:1 (1992), 25–39.
183. Saito, K., Nowak, T.S. Jr., Suyama, K., Quearry, B.J., Saito, M., Crowley, J.S., et al. Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation. Journal of Neurochemistry 61:6 (1993), 2061–2070.
184. Sapko, M.T., Guidetti, P., Yu, P., Tagle, D.A., Pellicciari, R., Schwarcz, R., Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: Implications for Huntington's disease. Experimental Neurology 197:1 (2006), 31–40, 10.1016/j.expneurol.2005.07.004.
185. Sarter, M., Nelson, C.L., Bruno, J.P., Cortical cholinergic transmission and cortical information processing in schizophrenia. Schizophrenia Bulletin 31:1 (2005), 117–138, 10.1093/schbul/sbi006.
186. Sathyasaikumar, K.V., Stachowski, E.K., Wonodi, I., Roberts, R.C., Rassoulpour, A., McMahon, R.P., et al. Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophrenia Bulletin 37:6 (2011), 1147–1156, 10.1093/schbul/sbq112.
187. Schousboe, A., Bak, L.K., Waagepetersen, H.S., Astrocytic control of biosynthesis and turnover of the neurotransmitters glutamate and GABA. Frontiers in Endocrinology (Lausanne), 4, 2013, 102, 10.3389/fendo.2013.00102.
188. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.-Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nature Reviews Neuroscience 13:7 (2012), 465–477, 10.1038/nrn3257.
189. Schwarcz, R., Du, F., Schmidt, W., Turski, W.A., Gramsbergen, J.B., Okuno, E., et al. Kynurenic acid: a potential pathogen in brain disorders. Annals of the New York Academy of Sciences 648 (1992), 140–153.
190. Schwarcz, R., Foster, A.C., French, E.D., Whetsell, W.O. Jr., Köhler, C., Excitotoxic models for neurodegenerative disorders. Life Sciences 35:1 (1984), 19–32.
191. Schwarcz, R., Rassoulpour, A., Wu, H.-Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biological Psychiatry 50:7 (2001), 521–530.
192. Schwieler, L., Larsson, M.K., Skogh, E., Kegel, M.E., Orhan, F., Abdelmoaty, S., et al. Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia - significance for activation of the kynurenine pathway. Journal of Psychiatry and Neuroscience 40:2 (2015), 126–133.
193. Schwieler, L., Pocivavsek, A., Liu, X., Giorgini, F., Muchowski, P.J., Engberg, G., et al. Behavioral and electrophysiological abnormalities in mice deficient in kynurenine 3-monooxygenase: relevance to schizophrenia. Society for Neuroscience Abstract, 39, 2014 51.18.
194. Severance, E.G., Alaedini, A., Yang, S., Halling, M., Gressitt, K.L., Stallings, C.R., et al. Gastrointestinal inflammation and associated immune activation in schizophrenia. Schizophrenia Research 138:1 (2012), 48–53, 10.1016/j.schres.2012.02.025.
195. Sharma, G., Vijayaraghavan, S., Nicotinic cholinergic signaling in hippocampal astrocytes involves calcium-induced calcium release from intracellular stores. Proceedings of the National Academy of Sciences of the United States of America 98:7 (2001), 4148–4153, 10.1073/pnas.071540198.
196. Shepard, P.D., Joy, B., Clerkin, L., Schwarcz, R., Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28:8 (2003), 1454–1462, 10.1038/sj.npp.1300188.
197. Shi, L., Fatemi, S.H., Sidwell, R.W., Patterson, P.H., Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. The Journal of Neuroscience 23:1 (2003), 297–302.
198. Sirota, P., Schild, K., Elizur, A., Djaldetti, M., Fishman, P., Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Progress in Neuropsychopharmacology and Biological Psychiatry 19:1 (1995), 75–83.
199. Sofroniew, M.V., Vinters, H.V., Astrocytes: biology and pathology. Acta Neuropathologica 119:1 (2010), 7–35, 10.1007/s00401-009-0619-8.
200. +-independent transporter of neutral amino acids in astrocytes. The Journal of Neuroscience 9:6 (1989), 2066–2072.
201. Speciale, C., Schwarcz, R., Uptake of kynurenine into rat brain slices. Journal of Neurochemistry 54:1 (1990), 156–163.
202. Speciale, C., Wu, H.-Q., Cini, M., Marconi, M., Varasi, M., Schwarcz, R., (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats. European Journal of Pharmacology 315:3 (1996), 263–267.
203. Speciale, C., Wu, H.-Q., Gramsbergen, J.B., Turski, W.A., Ungerstedt, U., Schwarcz, R., Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid. Neuroscience Letters 116:1–2 (1990), 198–203.
204. Stefansson, H., Ophoff, R.A., Steinberg, S., Andreassen, O.A., Cichon, S., Rujescu, D., et al. Common variants conferring risk of schizophrenia. Nature 460:7256 (2009), 744–747, 10.1038/nature08186.
205. Steffek, A.E., McCullumsmith, R.E., Haroutunian, V., Meador-Woodruff, J.H., Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophrenia Research 103:1–3 (2008), 71–82, 10.1016/j.schres.2008.04.032.
206. Stone, T.W., Perkins, M.N., Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. European Journal of Pharmacology 72:4 (1981), 411–412.
207. Stone, T.W., Stoy, N., Darlington, L.G., An expanding range of targets for kynurenine metabolites of tryptophan. Trends in Pharmacological Sciences 34:2 (2013), 136–143, 10.1016/j.tips.2012.09.006.
208. Swartz, K.J., During, M.J., Freese, A., Beal, M.F., Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors. The Journal of Neuroscience 10:9 (1990), 2965–2973.
209. Takahashi, N., Sakurai, T., Roles of glial cells in schizophrenia: possible targets for therapeutic approaches. Neurobiology of Disease 53 (2013), 49–60, 10.1016/j.nbd.2012.11.001.
210. Taniuchi, H., Hayaishi, O., Studies on the metabolism of kynurenic acid. III. Enzymatic formation of 7,8-dihydroxykynurenic acid from kynurenic acid. Journal of Biological Chemistry 238 (1963), 283–293.
211. Thomases, D.R., Flores-Barrera, E., Bruno, J.P., Schwarcz, R., Tseng, K.Y., Contribution of alpha-7 nAChR tone in sustaining the gain of GABAergic transmission in the adult prefrontal cortex. Society for Neuroscience Abstract, 39, 2014 33.02.
212. Thomson, A.M., Walker, V.E., Flynn, D.M., Glycine enhances NMDA-receptor mediated synaptic potentials in neocortical slices. Nature 338:6214 (1989), 422–424, 10.1038/338422a0.
213. Trecartin, K.V., Bucci, D.J., Administration of kynurenine during adolescence, but not during adulthood, impairs social behavior in rats. Schizophrenia Research 133:1–3 (2011), 156–158, 10.1016/j.schres.2011.08.014.
214. Turski, W.A., Gramsbergen, J.B., Traitler, H., Schwarcz, R., Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine. Journal of Neurochemistry 52:5 (1989), 1629–1636.
215. Turski, W.A., Nakamura, M., Todd, W.P., Carpenter, B.K., Whetsell, W.O. Jr., Schwarcz, R., Identification and quantification of kynurenic acid in human brain tissue. Brain Research 454:1–2 (1988), 164–169.
216. Turski, W.A., Schwarcz, R., On the disposition of intrahippocampally injected kynurenic acid in the rat. Experimental Brain Research 71:3 (1988), 563–567.
217. Uwai, Y., Honjo, H., Iwamoto, K., Interaction and transport of kynurenic acid via human organic anion transporters hOAT1 and hOAT3. Pharmacological Research 65:2 (2012), 254–260, 10.1016/j.phrs.2011.11.003.
218. Varasi, M., Della Torre, A., Heidempergher, F., Pevarello, P., Speciale, C., Guidetti, P., et al. Derivatives of kynurenine as inhibitors of rat brain kynurenine aminotransferase. European Journal of Medicinal Chemistry 31:1 (1996), 11–21.
219. Vécsei, L., Szalardy, L., Fülop, F., Toldi, J., Kynurenines in the CNS: recent advances and new questions. Nature Reviews Drug Discovery 12:1 (2013), 64–82, 10.1038/nrd3793.
220. Volk, D.W., Lewis, D.A., Prenatal ontogeny as a susceptibility period for cortical GABA neuron disturbances in schizophrenia. Neuroscience 248 (2013), 154–164, 10.1016/j.neuroscience.2013.06.008.
221. Vunck, S.A., Phenis, D., Tseng, K.Y., Schwarcz, R., Bruno, J.P., Rats exposed to elevated brain levels of kynurenic acid during the prenatal period exhibit an enhanced vulnerability to working memory deficits as adults. Society for Neuroscience Abstract, 39, 2014 51.11.
222. Vunck, S.A., Supe, K., Schwarcz, R., Bruno, J.P., Working memory deficits in adult rats after acute elevation of brain kynurenic acid are alleviated by co-administration of the alpha7 nicotinic positive modulator galantamine. Society for Neuroscience Abstract, 38, 2013 255.09.
223. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., et al. Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. Journal of Biological Chemistry 281:31 (2006), 22021–22028, 10.1074/jbc.M603503200.
224. Widner, B., Ledochowski, M., Fuchs, D., Interferon-gamma-induced tryptophan degradation: neuropsychiatric and immunological consequences. Current Drug Metabolism 1:2 (2000), 193–204.
225. Willette, A.A., Lubach, G.R., Knickmeyer, R.C., Short, S.J., Styner, M., Gilmore, J.H., et al. Brain enlargement and increased behavioral and cytokine reactivity in infant monkeys following acute prenatal endotoxemia. Behavioural Brain Research 219:1 (2011), 108–115, 10.1016/j.bbr.2010.12.023.
226. Wolfensberger, M., Amsler, U., Cuénod, M., Foster, A.C., Whetsell, W.O. Jr., Schwarcz, R., Identification of quinolinic acid in rat and human brain tissue. Neuroscience Letters 41:3 (1983), 247–252.
227. Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., et al. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Archives of General Psychiatry 68:7 (2011), 665–674, 10.1001/archgenpsychiatry.2011.71.
228. Wood, P.L., The co-agonist concept: is the NMDA-associated glycine receptor saturated in vivo?. Life Sciences 57:4 (1995), 301–310.
229. Wright, P., Gill, M., Murray, R.M., Schizophrenia: genetics and the maternal immune response to viral infection. American Journal of Medical Genetics 48:1 (1993), 40–46, 10.1002/ajmg.1320480110.
230. Wu, W.L., Adams, C.E., Stevens, K.E., Chow, K.H., Freedman, R., Patterson, P.H., The interaction between maternal immune activation and alpha 7 nicotinic acetylcholine receptor in regulating behaviors in the offspring. Brain, Behavior, and Immunity 46 (2015), 192–202, 10.1016/j.bbi.2015.02.005.
231. Wu, H.-Q., Okuyama, M., Kajii, Y., Pocivavsek, A., Bruno, J.P., Schwarcz, R., Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor. Schizophrenia Bulletin 40:Suppl 2 (2014), S152–S158, 10.1093/schbul/sbt157.
232. Wu, H.-Q., Pereira, E.F., Bruno, J.P., Pellicciari, R., Albuquerque, E.X., Schwarcz, R., The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. Journal of Molecular Neuroscience 40:1–2 (2010), 204–210, 10.1007/s12031-009-9235-2.
233. Wu, H.-Q., Rassoulpour, A., Schwarcz, R., Effect of systemic L-DOPA administration on extracellular kynurenate levels in the rat striatum. Journal of Neural Transmission 109:3 (2002), 239–249, 10.1007/s007020200020.
234. Wu, H.-Q., Rassoulpour, A., Schwarcz, R., Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain?. Journal of Neural Transmission 114:1 (2007), 33–41, 10.1007/s00702-006-0562-y.
235. Wu, H.-Q., Schwarcz, R., Seizure activity causes elevation of endogenous extracellular kynurenic acid in the rat brain. Brain Research Bulletin 39:3 (1996), 155–162.
236. Wu, H.-Q., Ungerstedt, U., Schwarcz, R., Regulation of kynurenic acid synthesis studied by microdialysis in the dorsal hippocampus of unanesthetized rats. European Journal of Pharmacology 213:3 (1992), 375–380.
237. Wu, H.-Q., Ungerstedt, U., Schwarcz, R., L-alpha-aminoadipic acid as a regulator of kynurenic acid production in the hippocampus: a microdialysis study in freely moving rats. European Journal of Pharmacology 281:1 (1995), 55–61.
238. Yamada, H., Yoshida, H., Nakazawa, H., Kumagai, H., Microbiological synthesis of L-tryptophan and its related amino acids. Acta Vitaminology and Enzymology 29:1–6 (1975), 248–251.
239. Yu, P., Di Prospero, N.A., Sapko, M.T., Cai, T., Chen, A., Melendez-Ferro, M., et al. Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Molecular Cell Biology 24:16 (2004), 6919–6930, 10.1128/MCB.24.16.6919-6930.2004.
240. Zavitsanou, K., Lim, C.K., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S.D., et al. Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: amelioration by COX-2 inhibition. Brain Behavior and Immunity 41 (2014), 173–181, 10.1016/j.bbi.2014.05.011.
241. Zmarowski, A., Wu, H.-Q., Brooks, J.M., Potter, M.C., Pellicciari, R., Schwarcz, R., et al. Astrocyte-derived kynurenic acid modulates basal and evoked cortical acetylcholine release. European Journal of Neuroscience 29:3 (2009), 529–538, 10.1111/j.1460-9568.2008.06594.x.